 Redburn initiated coverage of Boston's Vertex Pharmaceuticals with a bullish buy recommendation and a price target of $554 a share. I'm Bloomberg's Jeff Bellinger with New England Business on WBC, Boston's news radio. We'll have a report on the Karen Reid murder trial as we wait for a verdict coming up next at 1230.